Currently Viewing:
Newsroom
Currently Reading
Surgical Site Infections Common After Gastrointestinal Surgeries Worldwide
February 18, 2018 – Kaitlynn Ely
USPSTF Recommends Against Screening for Ovarian Cancer in Asymptomatic Women
February 18, 2018 – Jaime Rosenberg
Study Finds Merkel Cell Carcinoma Incidence Has Increased Since 2000
February 17, 2018 – Kaitlynn Ely
New ECPR Protocol Shows Increase in Survival of Some Cardiac Arrest Patients
February 17, 2018 – Samantha DiGrande
Anthem Changes to ED Payment Policy Leaves Some Unsatisfied
February 16, 2018 – Allison Inserro
5 Things Being Discussed and Addressed in Healthcare Spending
February 16, 2018 – Jaime Rosenberg
This Week in Managed Care: February 16, 2018
February 16, 2018
AJMC® in the Press, February 16, 2018
February 16, 2018 – AJMC Staff
Survey Identifies Barriers to Achieving Value-Based Care Models
February 16, 2018 – Kaitlynn Ely

Test Can Predict the Risk of Radiographic Progression in RA Patients

Alison Rodriguez
Patients with rheumatoid arthritis with high multi-biomarker disease activity scores have an increased risk of radiographic progression, according to a new analysis of 6 different studies.
Patients with rheumatoid arthritis (RA) with high multi-biomarker disease activity (MBDA) scores have an increased risk of radiographic progression (RP), according to a new analysis of 6 different studies. 

Patients with RA suffer from joint inflammation and joint damage and the MBDA test is able to analyze 12 serum protein biomarkers to quantify the level of disease activity in a patient’s body to a score between 1 and 100.

In a recent poster presented at the European League Against Rheumatism meeting in Madrid, Spain, researchers conducted a meta-analysis with the data collected from 6 subject groups in attempt to reveal the association between MBDA scores and RP risk in those suffering from RA. The patients in the 6 studies that were analyzed had to be receiving the RA treatment csDMARD, alone or in combination with adalimumab, infliximab or abatacept. 

Four of the subject groups reported their MBDA score (low, moderate, or high), at the beginning of the year while 2 reported at the end of the year to determine the frequency of RP throughout the course of 12 months. The study analyzed these results through categorizing each group with a positive predictive value (PPV) or negative predictive value based on patient comparisons with high MBDA scores versus low MBDA scores.

This data allowed the relative RP relative risk to be calculated. Results revealed evidence for frequent RP among patients with high MBDA scores in comparison to low or moderate MBDA scores, 3.6 to 9.5 (P = 0.002 to < 0.0001), for the individual studies. More specifically, the individual Leiden study, demonstrated that the MBDA score is the most significant predictor of RP. 

“The meta-analysis results, combined with published evidence that MBDA score used with clinical measures yields PPVs of ~60%, suggest that biomarkers can help stratify patients by their risk for RP,” the researchers concluded.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!